1. Home
  2. DBI vs BCYC Comparison

DBI vs BCYC Comparison

Compare DBI & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Designer Brands Inc.

DBI

Designer Brands Inc.

HOLD

Current Price

$6.70

Market Cap

375.2M

ML Signal

HOLD

Logo Bicycle Therapeutics plc

BCYC

Bicycle Therapeutics plc

HOLD

Current Price

$5.04

Market Cap

360.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DBI
BCYC
Founded
1991
2009
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
375.2M
360.7M
IPO Year
2005
2019

Fundamental Metrics

Financial Performance
Metric
DBI
BCYC
Price
$6.70
$5.04
Analyst Decision
Hold
Buy
Analyst Count
2
10
Target Price
$6.75
$13.90
AVG Volume (30 Days)
764.4K
587.0K
Earning Date
03-26-2026
04-30-2026
Dividend Yield
3.01%
N/A
EPS Growth
15.00
N/A
EPS
N/A
N/A
Revenue
$2,892,671,000.00
N/A
Revenue This Year
$1.29
N/A
Revenue Next Year
$1.88
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.18
$4.24
52 Week High
$8.75
$9.55

Technical Indicators

Market Signals
Indicator
DBI
BCYC
Relative Strength Index (RSI) 63.21 52.54
Support Level $6.47 $5.03
Resistance Level $7.59 $5.90
Average True Range (ATR) 0.41 0.25
MACD 0.18 0.09
Stochastic Oscillator 95.35 90.50

Price Performance

Historical Comparison
DBI
BCYC

About DBI Designer Brands Inc.

Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Share on Social Networks: